Results: The results demonstrate distinct dose-response and efficacy patterns across ST samples, with FAP-targeted RPT exhibiting limited effectiveness in tumor cell-rich areas compared to PSMA- and GRPR-targeted therapies. This evidence concerns the gene FAP and neoplasm.